advertisement
Cymbalta's package, label changed to cut errors
The U.S. Food and Drug Administration has announced changes in the packaging and labeling for Cymbalta. The packaging changes are designed to cut medication errors, including mix-ups with other drugs and confusion over dosing. Cymbalta's label has been updated to warn of of bleeding, falls, and urinary retention among some patients being treated with the med. Cymbalta is approved for use in patients with depression, generalized anxiety disorder, and diabetic neuropathy.
(MarketWatch) UPDATED 03/18/2008Click here to read the full story
Conditions: | depression - 327 Articles | diabetic neuropathy - 22 Articles | generalized anxiety disorder (GAD) - 48 Articles Treatments: | Cymbalta - 20 Articles
Helpful?
advertisement
